基本信息
浏览量:258
职业迁徙
个人简介
Clinical Interests:
Urologic Oncology (bladder, prostate, kidney, testes, and penile cancer)
Robotic, laparoscopic, and open surgery
Research Interests:
Biology and Therapy for Bladder Cancer
Molecular Markers for Bladder Cancer
Patterns of practice and outcomes in urologic oncology
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 300 peer-review manuscripts and book chapters. He is the founder of the national Canadian Bladder Cancer Network, a co-founder of Bladder Cancer Canada (BCC), co-chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. He has served as program director over the last 6 years and currently is a member of the Royal College Urology Examination board committee. Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award.
Upon his return to Canada, Dr Kassouf quickly realized that bladder cancer has not been fairly addressed in Canada and the rest of the world. Patient support group for bladder cancer needs to be more developed. On a global note, the actual prevalence of bladder cancer is ten times its incidence creating a major economic burden on health care systems. As measured on the basis of cumulative per patient cost from diagnosis until death, bladder cancer is the most expensive to treat. The lack of public awareness and patient advocacy, disproportionate research funding and decreasing research activity has limited progress in bladder cancer management. We (the medical community as well as patients) need to be more proactive with this disease. Through supporting Bladder Cancer Canada, we can help BCC fulfill its mission which include (1) help bladder cancer patients and their support team in the day-to-day issues with the disease, (2) raise awareness of bladder cancer among the general public and medical community, and (3) advocate for allocation of government and private funds directed to the diagnosis, treatment and medical research to eliminate bladder cancer.
Urologic Oncology (bladder, prostate, kidney, testes, and penile cancer)
Robotic, laparoscopic, and open surgery
Research Interests:
Biology and Therapy for Bladder Cancer
Molecular Markers for Bladder Cancer
Patterns of practice and outcomes in urologic oncology
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 300 peer-review manuscripts and book chapters. He is the founder of the national Canadian Bladder Cancer Network, a co-founder of Bladder Cancer Canada (BCC), co-chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. He has served as program director over the last 6 years and currently is a member of the Royal College Urology Examination board committee. Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award.
Upon his return to Canada, Dr Kassouf quickly realized that bladder cancer has not been fairly addressed in Canada and the rest of the world. Patient support group for bladder cancer needs to be more developed. On a global note, the actual prevalence of bladder cancer is ten times its incidence creating a major economic burden on health care systems. As measured on the basis of cumulative per patient cost from diagnosis until death, bladder cancer is the most expensive to treat. The lack of public awareness and patient advocacy, disproportionate research funding and decreasing research activity has limited progress in bladder cancer management. We (the medical community as well as patients) need to be more proactive with this disease. Through supporting Bladder Cancer Canada, we can help BCC fulfill its mission which include (1) help bladder cancer patients and their support team in the day-to-day issues with the disease, (2) raise awareness of bladder cancer among the general public and medical community, and (3) advocate for allocation of government and private funds directed to the diagnosis, treatment and medical research to eliminate bladder cancer.
研究兴趣
论文共 668 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
European Urology Oncology (2024)
Eva Michaud, Sabina Fehric,Gautier Marcq, JiaMin Huang,Fabio Cury,Madhuri Koti,José Joao Mansure,Ciriaco Piccirillo,Wassim Kassouf
Cancer Researchno. 6_Supplement (2024): 6641-6641
Cancersno. 2 (2024): 245
BRITISH JOURNAL OF PHARMACOLOGY (2024)
Cancer Researchno. 7_Supplement (2023): 5915-5915
引用0浏览0引用
0
0
crossref(2023)
The Journal of Urologyno. Supplement 4 (2023): E1124-E1124
Value in Healthno. 6 (2023): S66-S67
引用0浏览0引用
0
0
crossref(2023)
European Urology Open Science (2023): 22-29
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn